The study, a phase III trial conducted by researchers from New Jersey-based pharmaceutical company Bristol-Myers Squibb, tested an oral medication, daclatasvir, in combination with asunaprevir.
The study spanned 24 weeks. Subjects were of Asian descent -- but not Japanese -- and had been diagnosed with genotype 1b HCV, a strain of hepatitis that is common in China. Most Chinese patients diagnosed with genotype 1b HCV are treated with a combination of interferon and ribavirin.
The regimen tested was found to be effective.
Results from the trial were presented earlier this month during the Asian Pacific Association for the Study of the Liver Conference (APASL) in Tokyo, Japan.
Bristol-Myers Squibb is a global biopharmaceutical company.